Evidence map›Paper›PMID 36999007›Full record

ArticleHemaSphere2023

The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma.

Peiyu Yang, Fan Zhou, Yujun Dong, Guangxun Gao, Hua Xue, Xinyue Liang, Shanshan Yu, Weiling Xu, Yanping Ma, Xiaoqi Qin and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Peiyu YangDepartment of Hematology, First Hospital of Jilin University, Changchun, Jilin, China.
Fan ZhouDepartment of Hematology and Oncology, Shanghai Jing'an District Zhabei Central Hospital, Shanghai, China.
Yujun DongDepartment of Hematology, Peking University First Hospital, Beijing, China.
Guangxun GaoDepartment of Hematology, Xijing Hospital, Air Force Medical University, Xi'an, Shanxi, China.
Hua XueDepartment of Hematology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Xinyue LiangDepartment of Hematology, First Hospital of Jilin University, Changchun, Jilin, China.
Shanshan YuDepartment of Hematology, First Hospital of Jilin University, Changchun, Jilin, China.
Weiling XuDepartment of Radiology, First Hospital of Jilin University, Changchun, Jilin, China.
Yanping MaDepartment Hematology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xiaoqi QinDepartment Hematology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Mengyao LiDepartment of Hematology, First Hospital of Jilin University, Changchun, Jilin, China.
Yun DaiLaboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China.
Fengyan JinDepartment of Hematology, First Hospital of Jilin University, Changchun, Jilin, China.
First Hospital of Jilin University · CNJilin University · CNShanxi Medical University · CNAffiliated Hospital of Hebei University · CNAir Force Medical University · CNPeking University First Hospital · CNShanghai Zhabei District Shibei Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36999007
PMCPMC10043562
OpenAlexW4360826430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.